Plus Therapeutics appoints Ronald A. Andrews to board; Robert Lenk resigns

PLUS THERAPEUTICS, INC.

Robert Lenk resigned as director and Nominating Committee member effective March 20, 2026; no policy disagreement cited.
Ronald A. Andrews appointed to fill vacancy, effective immediately; will stand for reelection at 2026 annual meeting.
Andrews is independent under Nasdaq rules; appointed to Nominating and Corporate Governance Committee.
Andrews brings 35+ years in diagnostics; currently Founder/Managing Partner of The Bethesda Group.
No transactions requiring SEC disclosure; standard indemnification agreement expected.

item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-125195
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2026-03-26T23:59:59+00:00
discovered_at: 2026-05-14T18:02:34.533211+00:00
generated_at: 2026-05-15T08:46:52.663599+00:00
sec_items: ["5.02"]
event_type: leadership
sentiment: neutral
materiality_score: 0.3
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-125195
json_url: https://secwatch.observer/filing/0001193125-26-125195.json
markdown_url: https://secwatch.observer/filing/0001193125-26-125195.md
text_url: https://secwatch.observer/filing/0001193125-26-125195.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526125195/0001193125-26-125195-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526125195/pstv-20260320.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-125195

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.